Todd Young, the chief financial officer of Acadia Pharmaceuticals, recently joined another company.
His last day with Acadia will be Oct. 31.
An Acadia press release announcing the departure was mum on where he’s going, only saying “another health care company.” In 2016, Young came to Acadia from Baxalta, and prior to that was with Baxter International.
Elena Ridloff, senior vice president of investor relations, is set to become interim CFO.
“I want to thank Todd for his many contributions to the company and the finance function during an important period in ACADIA’s growth and wish him all the best in his future endeavors,” said Steve Davis, Acadia’s CEO.
Last month, the U.S. Food and Drug Administration reaffirmed Acadia’s drug, Nuplazid, after a reexamination. Nuplazid, a drug to treat hallucinations and delusions caused by Parkinson’s disease, was approved in 2016.
Acadia is looking to expand the use of Nuplazid in other indications.